Clazosentan

DB06677InvestigationalSmall molecule

Investigated for use/treatment in strokes.

Chemical structure of Clazosentan
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in strokes.Curator reviewed
Formula / weight
C25H23N9O6S · 577.58 g/mol (avg)
Code names
ACT-108475 · AXV-034343 · AXV-343434 · RO 61-1790 · VML-588

Resolves to

Compound
UNII3DRR0X4728CAS180384-56-9ChEMBLCHEMBL109648
Clinical / RWD
ATCC04AX33
Structure
InChIKeyLFWCJABOXHSRGC-UHFFFAOYSA-NSMILESCOC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C)C=N2)N=C(N=C1OCCO)C1=CC=NC(=C1)C1=NN=NN1
Targets
P25101EDNRA

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 6 drug categories
Sign in
7+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Clazosentan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In